Company News

19 09, 2023

BioProcess International – Cell & Gene Therapy Conference – 2023

2025-06-24T14:26:27+00:00

We are thrilled to announce that Avance Biosciences™ will be attending the highly anticipated Cell & Gene Therapy Manufacturing Conference, and we cordially invite you to join us! As a leader in advanced therapies, we understand the importance of staying at the forefront of cell and gene therapy innovation...

BioProcess International – Cell & Gene Therapy Conference – 20232025-06-24T14:26:27+00:00
29 08, 2023

Gene Therapy Potency Assay Summit – 2023

2025-06-24T14:26:27+00:00

We are thrilled to announce that Avance Biosciences™ will be attending the highly anticipated Gene Therapy Potency Assay Summit, and we cordially invite you to join us! As a leader in advanced therapies, we understand the importance of staying at the forefront of gene therapy innovation...

Gene Therapy Potency Assay Summit – 20232025-06-24T14:26:27+00:00
11 07, 2023

Enhancing Safety and Efficacy – Biodistribution Services for Advanced Cell and Gene Therapies

2025-06-24T14:33:19+00:00

As the field of advanced cell and gene therapies continues to grow exponentially, ensuring their safety and efficacy becomes paramount. Biodistribution studies, which evaluate the distribution of viral vectors and transgenes in the body, play a crucial role in pre-clinical pharmacokinetics and toxicity assessments...

Enhancing Safety and Efficacy – Biodistribution Services for Advanced Cell and Gene Therapies2025-06-24T14:33:19+00:00
31 05, 2023

Cell Therapy Potency Assay Summit – 2023

2025-06-24T14:26:28+00:00

Ensure the Success of Your Cell Therapy Drug Development - Avance Provides Assays to Support your Biopharmaceutical Development & Manufacturing - Avance Biosciences™ is a world-leading CRO specializing in GLP & GMP compliant biological assay development, assay validation, and [...]

Cell Therapy Potency Assay Summit – 20232025-06-24T14:26:28+00:00
9 05, 2023

NGS for ID and characterization of AAV genomes

2025-06-24T14:00:41+00:00

Adeno-associated virus (AAV) is a small, non-pathogenic, and non-enveloped virus that has become an important tool for gene therapy research and applications. AAV is a type of virus that requires a helper virus (such as adenovirus) to replicate, and it has a high degree of stability and safety, as it does not...

NGS for ID and characterization of AAV genomes2025-06-24T14:00:41+00:00
19 04, 2023

Potency testing for cellular and gene therapies

2025-06-24T14:04:57+00:00

Potency testing is an essential part of developing cellular and gene therapy (CGT) products. The US Food and Drug Administration (FDA) requires sponsors for Investigational New Drug (IND) and Biologics License Application (BLA) to provide in vitro or in vivo data to demonstrate the potency of the drug product...

Potency testing for cellular and gene therapies2025-06-24T14:04:57+00:00
11 04, 2023

Protein expression biodistribution studies

2025-06-24T14:33:52+00:00

Protein expression analysis is a critical process for researchers in the life sciences industry. The ability to accurately and reliably measure protein expression and distribution is essential for understanding the underlying biological mechanisms of disease and for developing effective therapeutic interventions...

Protein expression biodistribution studies2025-06-24T14:33:52+00:00
21 03, 2023

Biodistribution testing of cell and gene therapies

2025-06-24T14:34:35+00:00

Cell and gene therapy drug products represent a rapidly growing field in the development of new treatments for a wide range of diseases. These therapies have the potential to revolutionize medicine by offering cures rather than just managing symptoms. However, with this potential comes unique challenges, particularly with regard to biodistribution testing...

Biodistribution testing of cell and gene therapies2025-06-24T14:34:35+00:00
20 03, 2023

Gene Therapy for Rare Disorders – 2023

2025-06-24T14:26:28+00:00

Non-clinical and clinical studies that evaluate pharmacokinetic (ADME) and toxicology characteristics are essential to determine cellular and gene therapy (CGT) product safety and efficacy. Studies on gene vector and transgene biodistribution (BD), gene expression, protein expression, viral shedding, vector integration...

Gene Therapy for Rare Disorders – 20232025-06-24T14:26:28+00:00
7 03, 2023

Gene editing of human stem cells to treat rare disease

2025-06-24T13:28:55+00:00

Gene editing has the potential to transform the lives of patients with previously untreatable conditions, offering hope for a better future. As the technology continues to advance, it is likely that we will see more breakthroughs in this field in the coming years, bringing us closer to a world where rare diseases are...

Gene editing of human stem cells to treat rare disease2025-06-24T13:28:55+00:00
Go to Top